Improving digital ink interpretation through expected type prediction and dynamic dispatch

Thesis (M. Eng.)--Massachusetts Institute of Technology, Dept. of Electrical Engineering and Computer Science, 2008.This electronic version was submitted by the student author. The certified thesis is available in the Institute Archives and Special Collections.Includes bibliographical references (p. 67-70).Interpretation accuracy of current applications dependent on interpretation of handwritten "digital ink" can be improved by providing contextual information about an ink sample's expected type. This expected type, however, has to be known or provided a priori, and poses several challenges if unknown or ambiguous. We have developed a novel approach that uses a classic machine learning technique to predict this expected type from an ink sample. By extracting many relevant features from the ink, and performing generic dimensionality reduction, we can obtain a minimum prediction accuracy of 89% for experiments involving up to five different expected types. With this approach, we can create a "dynamic dispatch interpreter" by biasing interpretation differently according to the predicted expected types of the ink samples. When evaluated in the domain of introductory computer science, our interpreter achieves high interpretation accuracy (87%), an improvement from Microsoft's default interpreter (62%), and comparable with other previous interpreters (87-89%), which, unlike ours, require additional expected type information for each ink sample.by Kah Seng Tay.M.Eng

Self and parent-proxy rated health-related quality of life (HRQoL) in youth with obesity: are parents good surrogates?

10.1007/s11136-020-02472-yQUALITY OF LIFE RESEARCH2982171-218

Prevalence and predictors of metabolically healthy obesity in severely obese Asian children.

10.1038/s41390-022-01941-zPediatr Re

Association of leukocyte telomere length with obesity-related traits in Asian children with early-onset obesity

10.1111/ijpo.12771PEDIATRIC OBESITY16

Empagliflozin in Patients with Chronic Kidney Disease

Background The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients. Methods We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m(2) of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m(2) with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200. Patients were randomly assigned to receive empagliflozin (10 mg once daily) or matching placebo. The primary outcome was a composite of progression of kidney disease (defined as end-stage kidney disease, a sustained decrease in eGFR to < 10 ml per minute per 1.73 m(2), a sustained decrease in eGFR of & GE;40% from baseline, or death from renal causes) or death from cardiovascular causes. Results A total of 6609 patients underwent randomization. During a median of 2.0 years of follow-up, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% confidence interval [CI], 0.64 to 0.82; P < 0.001). Results were consistent among patients with or without diabetes and across subgroups defined according to eGFR ranges. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.86; 95% CI, 0.78 to 0.95; P=0.003), but there were no significant between-group differences with respect to the composite outcome of hospitalization for heart failure or death from cardiovascular causes (which occurred in 4.0% in the empagliflozin group and 4.6% in the placebo group) or death from any cause (in 4.5% and 5.1%, respectively). The rates of serious adverse events were similar in the two groups. Conclusions Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo